Web@article{Dranoff2004CytokinesIC, title={Cytokines in cancer pathogenesis and cancer therapy}, author={Glenn Dranoff}, journal={Nature Reviews Cancer}, year={2004}, volume={4}, pages={11-22} } ... G. Dranoff; Published 2004; Biology, Medicine; Nature Reviews Cancer; The mixture of cytokines that is produced in the tumour … WebFeb 1, 2004 · Adapted from Dranoff G. 2004. Nature Reviews Cancer (3) and created with BioRender.com. ... T-BET and EOMES: the powerful pair in human NK cell differentiation …
Current status and future directions of cancer immunotherapy
WebMar 24, 2024 · Insights into the effects of targeted therapies, conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies ... WebDec 1, 2005 · In this issue of Clinical Cancer Research, Wolf and colleagues present compelling evidence that underscores a key role for regulatory T cell–induced immune suppression in tumor pathogenesis (1). Although most cancer patients mount innate and adaptive antitumor reactions, the evolution of clinically evident disease implies a failure … net invisible receipts
Cytokines in cancer pathogenesis and cancer therapy - Nature
WebErratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 (Nature Communications, (2024), 8, 1, (14922), 10.1038/ncomms14922) WebMay 9, 2024 · From the reviews: “This book comprises 13 reviews, contributed by members of a cross-section of groups working in the … field of cancer immunology. … this book is at its best when considering small and apparently discrete topics – its strength comes from being able to read all of these ideas on one place. … WebAbstract. Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. net investment solow